Ubs Asset Management Americas Inc Arcus Biosciences, Inc. Transaction History

Ubs Asset Management Americas Inc

  • $381 Billion
  • Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 69,886 shares of RCUS stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69,886
Previous 96,852 27.84%
Holding current value
$1.11 Million
Previous $1.48 Million 27.59%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$13.69 - $18.01 $369,164 - $485,657
-26,966 Reduced 27.84%
69,886 $1.07 Million
Q2 2024

Aug 13, 2024
SELL
$14.59 - $18.48 $4.1 Million - $5.2 Million
-281,211 Reduced 74.38%
96,852 $1.48 Million
Q1 2024

May 15, 2024
SELL
$14.83 - $20.18 $305,542 - $415,768
-20,603 Reduced 5.17%
378,063 $7.14 Million
Q4 2023

Feb 14, 2024
SELL
$13.43 - $19.63 $99,126 - $144,889
-7,381 Reduced 1.82%
398,666 $7.61 Million
Q3 2023

Nov 13, 2023
SELL
$17.62 - $23.54 $92,557 - $123,655
-5,253 Reduced 1.28%
406,047 $7.29 Million
Q1 2023

May 15, 2023
BUY
$15.96 - $23.15 $152,114 - $220,642
9,531 Added 2.37%
411,300 $7.5 Million
Q4 2022

Feb 14, 2023
SELL
$19.7 - $35.71 $885,810 - $1.61 Million
-44,965 Reduced 10.07%
401,769 $8.31 Million
Q3 2022

Nov 14, 2022
SELL
$23.23 - $30.07 $88,761 - $114,897
-3,821 Reduced 0.85%
446,734 $11.7 Million
Q2 2022

Aug 12, 2022
BUY
$17.23 - $37.73 $2.36 Million - $5.16 Million
136,717 Added 43.56%
450,555 $11.4 Million
Q1 2022

May 16, 2022
BUY
$28.92 - $41.83 $2.1 Million - $3.04 Million
72,627 Added 30.11%
313,838 $9.9 Million
Q4 2021

Feb 14, 2022
BUY
$31.38 - $48.47 $6.26 Million - $9.68 Million
199,634 Added 480.15%
241,211 $9.76 Million
Q3 2021

Nov 15, 2021
BUY
$26.93 - $37.68 $122,720 - $171,707
4,557 Added 12.31%
41,577 $1.45 Million
Q2 2021

Aug 16, 2021
BUY
$22.75 - $35.77 $82,673 - $129,988
3,634 Added 10.88%
37,020 $1.02 Million
Q1 2021

May 14, 2021
SELL
$26.16 - $41.39 $113,246 - $179,177
-4,329 Reduced 11.48%
33,386 $937,000
Q4 2020

Mar 01, 2021
BUY
$17.0 - $32.36 $253,555 - $482,649
14,915 Added 65.42%
37,715 $979,000
Q3 2020

Nov 13, 2020
SELL
$17.14 - $25.47 $137,377 - $204,142
-8,015 Reduced 26.01%
22,800 $390,000
Q2 2020

Aug 14, 2020
BUY
$13.97 - $36.56 $430,485 - $1.13 Million
30,815 New
30,815 $762,000
Q2 2018

Aug 14, 2018
SELL
$12.24 - $17.05 $509,820 - $710,166
-41,652 Closed
0 $0
Q1 2018

May 14, 2018
BUY
$15.44 - $17.71 $643,106 - $737,656
41,652 New
41,652 $0

Others Institutions Holding RCUS

# of Institutions
200
Shares Held
51.5M
Call Options Held
236K
Put Options Held
141K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.14B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email